In the News

Organoids Touted as Future of Brain Disorder R&D as AxoSim Scoops Up Tech from Vyant Subsidiary

October 24, 2023
Loading the Elevenlabs Text to Speech AudioNative Player...
As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech.

Related Stories

In the News
5/12/2026
28bio Launches CNS-3D Myelinated Organoids to Predict Therapeutic Efficacy
Spotlight
5/7/2026
28bioGRANT for Neurodegenerative Disease Awardees Announced
28bio announces the 2026 recipients of the 28bioGRANT for Neurodegenerative Disease, supporting innovative research in CNS-targeted nanotherapeutics and human iPSC-based Alzheimer’s disease modeling.
In the News
3/23/2026
28bio’s Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability
28bio reports Endurance Study results showing brain organoids predict clinical seizure liability with 83% sensitivity and 89% specificity.
Join our mailing list.
Thank you! Your submission has been received.
Something went wrong while submitting the form.
© 2025 28bio. All rights reserved.
Privacy Policy
Terms of Use
FCOI Polcy